Pharma BD Deal Intelligence
Evotec and Bristol Myers Squibb progress their strategic partnership in neurodegeneration, leveraging Evotec's modality-agnostic precision medicine platforms…
Evotec and Bristol Myers Squibb advance their neuroscience partnership, with the first program EVT8683 progressing into clinical Phase I following successful…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
BMS extended and expanded its strategic neurodegeneration partnership with Evotec for 8 additional years, building on their 2016 collaboration including clinical-stage EVT8683.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bristol-Myers Squibb Company / Evotec SE (this deal) | 2023 | $4.0B | 66 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Bristol-Myers Squibb Company / MyoKardia Inc. | 2020 | $13.1B | 76 |
| Bristol-Myers Squibb Company / Karuna Therapeutics | 2023 | $14.0B | 76 |
| Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. | 2011 | — | 76 |
| Bristol-Myers Squibb Company / SystImmune Inc. | 2023 | $8.4B | 71 |
← Browse all deals · How we score deals
More: 2023 deals · Bristol-Myers Squibb Company deals · Neurology deals